Mortality and costs of acute renal failure associated with amphotericin B therapy

Clin Infect Dis. 2001 Mar 1;32(5):686-93. doi: 10.1086/319211. Epub 2001 Feb 21.


To assess the mortality and resource utilization that results from acute renal failure associated with amphotericin B therapy, 707 adult admissions in which parenteral amphotericin B therapy was given were studied at a tertiary-care hospital. Main outcome measures were mortality, length of stay, and costs; we controlled for potential confounders, including age, sex, insurance status, baseline creatinine level, length of stay before beginning amphotericin B therapy, and severity of illness. Among 707 admissions, there were 212 episodes (30%) of acute renal failure. When renal failure developed, the mortality rate was much higher: 54% versus 16% (adjusted odds of death, 6.6). When acute renal failure occurred, the mean adjusted increase in length of stay was 8.2 days, and the adjusted total cost was $29,823. Although residual confounding exists despite adjustment, the increases in resource utilization that we found are large and the associated mortality is high when acute renal failure occurs following amphotericin B therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / economics*
  • Acute Kidney Injury / mortality*
  • Adult
  • Amphotericin B / adverse effects*
  • Antifungal Agents / adverse effects*
  • Cohort Studies
  • Female
  • Hospital Costs
  • Hospitalization / economics
  • Hospitals, Urban
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Retrospective Studies


  • Antifungal Agents
  • Amphotericin B